Published in Lancet Infect Dis on August 01, 2002
The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis (2010) 2.96
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis (2006) 1.48
Occult HBV infection. Semin Immunopathol (2012) 1.37
An overview of occult hepatitis B virus infection. World J Gastroenterol (2011) 1.32
Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis (2010) 1.32
Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev (2012) 1.30
Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev (2007) 1.20
Epidemiologic study of chronic hepatitis B virus infection in male volunteer blood donors in Karachi, Pakistan. BMC Gastroenterol (2005) 1.18
Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis (2008) 1.17
Real-time PCR assay for detection and quantification of hepatitis B virus genotypes A to G. J Clin Microbiol (2006) 1.13
Naturally occurring mutations in large surface genes related to occult infection of hepatitis B virus genotype C. PLoS One (2013) 1.11
Molecular characteristics and stages of chronic hepatitis B virus infection. World J Gastroenterol (2009) 1.10
Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol (2007) 1.09
Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis (2008) 1.04
Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. Clin Infect Dis (2007) 1.01
Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol (2009) 0.99
Occult hepatitis B virus infection in anti-HBs-positive infants born to HBsAg-positive mothers in China. PLoS One (2013) 0.98
Post-transfusion occult hepatitis B (OBI): a global challenge for blood recipients and health authorities. Hepat Mon (2011) 0.97
Pathogenesis of occult chronic hepatitis B virus infection. World J Gastroenterol (2011) 0.97
Detection of hepatitis B virus DNA among accepted blood donors in Nanjing, China. Virol J (2010) 0.97
Occult hepatitis B virus infection: A major concern in HIV-infected patients: Occult HBV in HIV. Hepat Mon (2011) 0.95
Detection of T lymphocyte subsets and mIL-2R on surface of PBMC in patients with hepatitis B. World J Gastroenterol (2003) 0.95
Management of occult hepatitis B virus infection: an update for the clinician. World J Gastroenterol (2011) 0.94
Epidemiology of occult hepatitis B infection among thalassemic, hemophilia, and hemodialysis patients. Hepat Mon (2012) 0.94
Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. J Gastroenterol (2009) 0.94
Diagnostic strategy for occult hepatitis B virus infection. World J Gastroenterol (2011) 0.92
A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol (2007) 0.91
Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein. Hepatol Int (2010) 0.90
Occult hepatitis B virus infection. World J Hepatol (2014) 0.90
Controversies about occult hepatitis B virus infection. World J Gastroenterol (2009) 0.88
Atypical serological profiles in hepatitis B virus infection. Eur J Clin Microbiol Infect Dis (2012) 0.88
Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology (2014) 0.87
Occult infection related hepatitis B surface antigen variants showing lowered secretion capacity. World J Gastroenterol (2015) 0.87
Occult hepatitis B virus infection: a case of reactivation in a patient receiving immunosuppressive treatment for allogeneic bone marrow transplantation. Blood Transfus (2008) 0.86
A computational approach to identify point mutations associated with occult hepatitis B: significant mutations affect coding regions but not regulative elements of HBV. Virol J (2011) 0.86
Occult Hepatitis B (OBH) in Clinical Settings. Hepat Mon (2012) 0.86
Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol (2011) 0.86
Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol (2014) 0.85
Prevalence of markers of hepatitis B virus infection or vaccination in HBsAg-negative subjects. Blood Transfus (2012) 0.85
Enhanced cell disruption strategy in the release of recombinant hepatitis B surface antigen from Pichia pastoris using response surface methodology. BMC Biotechnol (2012) 0.84
Prevalence of occult hepatitis B virus infection in a cohort of HIV-positive patients resident in Sicily, Italy. Biomed Res Int (2013) 0.84
Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat (2013) 0.84
Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients? Dig Dis Sci (2006) 0.84
Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol (2014) 0.84
Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol (2014) 0.84
The underlying mechanisms for the "simultaneous HBsAg and anti-HBs serological profile". Eur J Clin Microbiol Infect Dis (2011) 0.84
Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes. World J Gastroenterol (2011) 0.83
The clinical significance of occult HBV infection. Ann Gastroenterol (2014) 0.83
Occult hepatitis B in blood donors: a description of two cases. Blood Transfus (2010) 0.83
Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study. World J Gastroenterol (2013) 0.83
Risk of hepatitis B infections in Olympic wrestling. Br J Sports Med (2007) 0.83
Recent advances in molecular diagnostics of hepatitis B virus. World J Gastroenterol (2014) 0.83
Epidemiology and molecular characterization of hepatitis B virus infection in isolated villages in the Western Brazilian Amazon. Am J Trop Med Hyg (2012) 0.83
Expression of Hepatitis B Virus Surface Antigen Containing Y100C Variant Frequently Detected in Occult HBV Infection. Hepat Res Treat (2011) 0.82
Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis. World J Hepatol (2010) 0.82
Genetic variation of hepatitis B virus and its significance for pathogenesis. World J Gastroenterol (2016) 0.82
Quantification of pregenomic RNA and covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma. Int J Hepatol (2013) 0.81
Occult hepatitis B viral infection among blood donors in South-Eastern Nigeria. Pathog Glob Health (2014) 0.81
New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology. World J Gastroenterol (2004) 0.81
Management of hepatitis B in patients coinfected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis (2004) 0.81
Occult Hepatitis B Virus Infection among HIV Positive Patients in Nigeria. J Trop Med (2014) 0.81
Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study. BMC Cancer (2012) 0.80
Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol (2008) 0.80
Occult hepatitis B virus infection in Lebanese patients with chronic hepatitis C liver disease. Eur J Clin Microbiol Infect Dis (2008) 0.80
Occult hepatitis B among Iranian hepatitis C patients. J Res Med Sci (2009) 0.79
Maternal hepatitis B and infant infection among pregnant women living with HIV in South Africa. J Int AIDS Soc (2014) 0.79
Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol (2015) 0.79
Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol (2015) 0.79
Association of preS/S Mutations with Occult Hepatitis B Virus (HBV) Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants. Int J Mol Sci (2015) 0.79
Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus Transmission Risks. PLoS One (2015) 0.78
Clinical significance of occult hepatitis B virus infection in chronic hepatitis C patients. Korean J Hepatol (2011) 0.78
Identification of substance use and dependence among patients with viral hepatitis. Dig Liver Dis (2010) 0.78
Occult hepatitis B virus infection among blood donors in Colombia. Virol J (2014) 0.78
Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma. PLoS One (2013) 0.78
Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med (2011) 0.78
Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis. J Cancer (2013) 0.78
Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis. J Gastroenterol (2013) 0.78
Viral hepatitis in hemodialysis: An update. J Transl Int Med (2015) 0.78
Clinical significance of antibody to hepatitis B core antigen in multitransfused hemodialysis patients. Asian J Transfus Sci (2009) 0.78
Hepatitis B virus surface antigen (HBsAg)-positive and HBsAg-negative hepatitis B virus infection among mother-teenager pairs 13 years after neonatal hepatitis B virus vaccination. Clin Vaccine Immunol (2012) 0.77
Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur J Clin Microbiol Infect Dis (2015) 0.77
HIV infection and hepatitis B seroprevalence among antenatal clinic attendees in Niger, West Africa. HIV AIDS (Auckl) (2012) 0.77
Effects of autoantibodies against beta(1)-adrenoceptor in hepatitis virus myocarditis on action potential and L-type Ca(2+) currents. World J Gastroenterol (2004) 0.77
Anti-HBV activity of TRL mediated by recombinant adenovirus. World J Gastroenterol (2005) 0.77
Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy. Hepat Mon (2012) 0.77
Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: A review of prevalence, diagnosis and clinical significance. World J Hepatol (2015) 0.76
Occult hepatitis B virus infection among Mexican human immunodeficiency virus-1-infected patients. World J Gastroenterol (2014) 0.76
Investigation of occult hepatitis B virus infection in anti-hbc positive patients from a liver clinic. PLoS One (2015) 0.76
Occult hepatitis B virus infection in Egypt. World J Hepatol (2015) 0.76
Occult hepatitis B: Evolving challenges and new perspectives. Hepat Mon (2011) 0.76
An occult hepatitis B-derived hepatoma cell line carrying persistent nuclear viral DNA and permissive for exogenous hepatitis B virus infection. PLoS One (2013) 0.76
Mutations associated with occult hepatitis B in HIV-positive South Africans. J Med Virol (2014) 0.76
Prevalence of Hepatitis B Co-Infection among HIV Positive Patients: Narrative Review Article. Iran J Public Health (2014) 0.75
Inhibition of HBV targeted ribonuclease enhanced by introduction of linker. World J Gastroenterol (2003) 0.75
Occult hepatitis B virus infection in liver transplant patients in a Brazilian referral center. Braz J Med Biol Res (2014) 0.75
Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India. PLoS One (2017) 0.75
Occult hepatitis B infection in patients with cryptogenic liver cirrhosis in southwest of iran. Jundishapur J Microbiol (2015) 0.75
Limited infection with occult hepatitis B virus in drug users in the USA. Hepatol Res (2012) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
Hepatitis C virus infection and incident type 2 diabetes. Hepatology (2003) 1.89
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology (2002) 1.65
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health (2004) 1.62
Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis (2003) 1.57
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53
Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol (2003) 1.52
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS (2004) 1.44
Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses (2006) 1.42
Prospective study of infective endocarditis among injection drug users. J Infect Dis (2002) 1.41
Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis. Clin Infect Dis (2012) 1.41
HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med (2013) 1.41
Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology (2006) 1.38
Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med (2004) 1.36
High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J (2006) 1.36
Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology (2002) 1.35
Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol (2004) 1.34
Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology (2014) 1.29
CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load. Clin Infect Dis (2008) 1.29
Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis (2010) 1.28
Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend (2004) 1.28
High frequency of false-positive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda. Clin Infect Dis (2013) 1.26
Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J Clin Microbiol (2004) 1.26
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A (2007) 1.24
Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology (2013) 1.23
High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology (2004) 1.23
Association of CTLA4 polymorphism with regulatory T cell frequency. Eur J Immunol (2005) 1.22
The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr (2003) 1.19
Mannose binding lectin genotypes influence recovery from hepatitis B virus infection. J Virol (2005) 1.19
Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. J Infect Dis (2013) 1.18
Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol (2006) 1.17
The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology (2005) 1.17
High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend (2005) 1.17
Epistatic effects of immunoglobulin GM and KM allotypes on outcome of infection with hepatitis C virus. J Virol (2004) 1.16
The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr (2003) 1.13
CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. J Infect Dis (2011) 1.12
Screening for HCV infection in jails. JAMA (2012) 1.11
Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. J Hepatol (2010) 1.10
Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol (2007) 1.10
Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology (2014) 1.08
The chronic vascular and haemodynamic response after permanent bilateral common carotid occlusion in newborn and adult rats. J Cereb Blood Flow Metab (2006) 1.07
Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE). J Urban Health (2007) 1.06
High-resolution functional MRI at 3 T: 3D/2D echo-planar imaging with optimized physiological noise correction. Magn Reson Med (2012) 1.05
Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort. J Infect Dis (2011) 1.04
High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis (2011) 1.04
Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis (2008) 1.04
Hepatitis C in the HIV-infected patient. Clin Liver Dis (2003) 1.03
Risk factors for hepatitis C virus infection among blood donors in northern Thailand. Transfusion (2004) 1.03
HCV reinfection studies and the door to vaccine development. J Hepatol (2009) 1.02
CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection. J Infect Dis (2007) 1.01
Detection of microbial translocation in HIV and SIV infection using the Limulus amebocyte lysate assay is masked by serum and plasma. PLoS One (2012) 1.01
Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA. AIDS (2003) 1.00
Cardiac arterial spin labeling using segmented ECG-gated Look-Locker FAIR: variability and repeatability in preclinical studies. Magn Reson Med (2012) 1.00
Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS (2009) 1.00
Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment". Hepatology (2012) 1.00
Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol (2007) 1.00
Association of hepatitis C virus infection with sexual exposure in southern India. Clin Infect Dis (2003) 0.99